SG Americas Securities
BIOA

SG Americas Securities’s BioAge Labs BIOA Stock Holding History

SG Americas Securities’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,174
Closed -$59K – 3818
2024
Q4 		$59K Buy
+10,174
New +$175K ﹤0.01% 2877

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

SG Americas Securities's BIOA Position: Q1 2025 in Review

SG Americas Securities sold out of BioAge Labs (BIOA) in Q1 2025, closing a stake of 10,174 shares — an estimated $59K sold.

SG Americas Securities first reported a position in BIOA in Q4 2024 and held it in 1 quarter. The position peaked at $59K in Q4 2024. 67 funds tracked by Wall St. Rank hold BIOA as of Q1 2025.

  • SG Americas Securities reported no remaining BioAge Labs position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 10,174 BioAge Labs shares in Q1 2025, an estimated $59K.
  • SG Americas Securities first reported a position in BioAge Labs in Q4 2024 and held it in 1 quarter.
  • SG Americas Securities's BioAge Labs position peaked at $59K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.